Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.

A cyclic analogue, [cyclo(87-99)MBP(87)(-)(99)], of the human immunodominant MBP(87)(-)(99) epitope, was designed based on ROESY/NMR distance information and modeling data for linear epitope 87-99, taking into account T-cell (Phe(89), Lys(91), Pro(96)) and HLA (His(88), Phe(90), Ile(93)) contact side-chain information. The cyclic analogue was found to induce experimental allergic encephalomyelitis (EAE), to bind HLA-DR4, and to increase CD4 T-cell line proliferation, like that of the conformationally related linear MBP(87)(-)(99) epitope peptide. The mutant cyclic peptides, the cyclo(91-99)[Ala(96)]MBP(87)(-)(99) and the cyclo(87-99)[Arg(91)Ala(96)]MBP(87)(-)(99), reported previously for suppressing, to a varying degree, autoimmune encephalomyelitis in a rat animal model, were found in this study to possess the following immunomodulatory properties: (i) they suppressed the proliferation of a CD4 T-cell line raised from a multiple sclerosis patient, (ii) they scored the best in vitro TH2/TH1 cytokine ratio in peripheral blood mononuclear cell cultures derived from 13 multiple sclerosis patients, inducing IL-10 selectively, and (iii) they bound to HLA-DR4, first to be reported for cyclic MBP peptides. In addition, cyclic peptides were found to be more stable to lysosomal enzymes and Cathepsin B, D, and H, compared to their linear counterparts. Taken together, these data render cyclic mimics as putative drugs for treating multiple sclerosis and potentially other Th1-mediated autoimmune diseases.

[1]  T Mavromoustakos,et al.  Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. , 2000, Bioorganic & medicinal chemistry letters.

[2]  H. Weiner,et al.  Immunologic Mechanisms and Therapy in Multiple Sclerosis , 1995, Immunological reviews.

[3]  Lawrence Steinman,et al.  Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.

[4]  L. Steinman,et al.  Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms , 1997, Journal of Neuroimmunology.

[5]  T Mavromoustakos,et al.  Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists. , 2001, Bioorganic & medicinal chemistry.

[6]  Dimitrios Morikis,et al.  The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR* 210 , 2002, The Journal of Biological Chemistry.

[7]  R. Hohlfeld,et al.  Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.

[8]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[9]  Dimitrios Gatos,et al.  Synthesis of Prothymosin α (ProTα)—a Protein Consisting of 109 Amino Acid Residues , 1991 .

[10]  T Mavromoustakos,et al.  The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II. , 2000, Bioorganic & medicinal chemistry.

[11]  G. Kollias,et al.  Design and synthesis of small semi-mimetic peptides with immunomodulatory activity based on Myelin Basic Protein (MBP) , 2005, Amino Acids.

[12]  J. Poolman,et al.  Simultaneous multiple synthesis and selective conjugation of cyclized peptides derived from a surface loop of a meningococcal class 1 outer membrane protein. , 2009, International journal of peptide and protein research.

[13]  R. Pedotti,et al.  An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide , 2001, Nature Immunology.

[14]  R. Zubler,et al.  Occurrence of a silencer of the interleukin‐2 gene in naive but not in memory resting T helper lymphocytes , 1993, European journal of immunology.

[15]  D. McFarlin,et al.  Immunological aspects of demyelinating diseases. , 1992, Annual review of immunology.

[16]  A. Sette,et al.  A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. , 1994, Journal of immunology.

[17]  Theodore V. Tselios,et al.  Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. , 2002, Journal of medicinal chemistry.

[18]  D. Andreu,et al.  Synthesis of cyclic herpes simplex virus peptides containing 281–284 epitope of glycoprotein D‐1 in endo‐ or exo‐position , 1999, Journal of peptide science : an official publication of the European Peptide Society.

[19]  D. Wraith.  Role of interleukin-10 in the induction and function of natural and antigen-induced regulatory T cells. , 2003, Journal of autoimmunity.

[20]  Andreas Plückthun,et al.  Circular β‐lactamase: stability enhancement by cyclizing the backbone , 1999 .

[21]  Lawrence Steinman,et al.  Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year , 2003, The Journal of experimental medicine.

[22]  A. Vandenbark,et al.  Selectin of encephalitogenic rat T‐Lymphocyte clones recognizing an immunodominant epitope on myelin basic protein , 1989, Journal of neuroscience research.

[23]  L. Berezhkovskiy,et al.  Synthesis and kinetics of cyclization of MHC class II-derived cyclic peptide vaccine for diabetes. , 1999, The journal of peptide research : official journal of the American Peptide Society.

[24]  L. Weiner,et al.  Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. , 1995, Journal of immunology.

[25]  Biological and structural properties of cyclic peptides derived from the alpha-amylase inhibitor tendamistat. , 1998, Bioscience, biotechnology, and biochemistry.

[26]  H. Kalbacher,et al.  A rapid method to separate endosomes from lysosomal contents using differential centrifugation and hypotonic lysis of lysosomes. , 1999, Journal of immunological methods.

[27]  Panagiotis Zoumpoulakis,et al.  Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges. Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[28]  U. Utz,et al.  Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein , 1996, Nature.

[29]  G. Pawelec,et al.  Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia). , 2000, Blood.

[30]  Theodore V. Tselios,et al.  Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides. , 2000, Bioorganic & medicinal chemistry.

[31]  T. Rana,et al.  Design, synthesis, and biological activity of a cyclic peptide: an inhibitor of HIV-1 tat-TAR interactions in human cells. , 2000, Bioorganic & medicinal chemistry letters.

[32]  G. Moore,et al.  Role of myelin basic protein epitope MBP74‐85 in experimental autoimmune encephalomyelitis: Elaboration of agonist and antagonist motifs , 1999 .

[33]  A. Evans,et al.  Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.

[34]  T Mavromoustakos,et al.  Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. , 1999, Journal of medicinal chemistry.

[35]  C. Polman,et al.  New and emerging treatment options for multiple sclerosis , 2003, The Lancet Neurology.

[36]  V. Gnau,et al.  A 16mer peptide of the human autoantigen calreticulin is a most prominent HLA-DR4Dw4-associated self-peptide. , 1994, Human immunology.

[37]  K Barlos,et al.  Novel synthesis of cyclic amide-linked analogues of angiotensins II and III. , 1994, Journal of medicinal chemistry.

[38]  J. Strominger,et al.  Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. , 1987, The Journal of biological chemistry.

[39]  N. Solvason,et al.  A conformationally-constrained MHC class II I-Ag7-derived peptide protects NOD mice from the development of diabetes. , 1999, Journal of autoimmunity.

[40]  M. Hollenberg,et al.  Synthesis and contractile activities of cyclic thrombin receptor-derived peptide analogues with a Phe-Leu-Leu-Arg motif: importance of the Phe/Arg relative conformation and the primary amino group for activity. , 1996, Journal of Medicinal Chemistry.

[41]  U. Utz,et al.  Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99) , 1996, European journal of immunology.

[42]  L Steinman,et al.  Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.

[43]  N. Viner,et al.  Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP , 2002, Nature Immunology.

[44]  P. Allen,et al.  Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells , 1993, Nature.

[45]  K. Garcia,et al.  A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. , 2000, Immunity.

[46]  H. McFarland,et al.  A novel population of CD4+CD56+ myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. , 1996, Journal of immunology.

[47]  Martin Deeg,et al.  Cathepsin S and an asparagine‐specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro , 2001, European journal of immunology.

[48]  D. Wraith,et al.  Selection and fine-tuning of the autoimmune T-cell repertoire , 2002, Nature Reviews Immunology.